Skip to main content
. 2022 Mar 29;18:669–679. doi: 10.2147/NDT.S349427

Table 3.

The PSG Indicators of Pre- and Post-Treatment in the Shumian Capsule Group and the Placebo Group

Variable Shumian Capsule Group (n =8) Placebo Capsule Group (n=11) P1 P2 P3
Pre-Treatment Post-Treatment Pre-Treatment Post-Treatment
Total sleep time, min 368.88 ± 18.65 445.31 ± 16.31 336.64 ± 28.27 356.73 ± 16.87 0.040 0.081 0.496
Sleep latency, min 27.70 (27.70) 20.05 (21.23) 33.90 (85.10) 46.30 (78.40) 0.111 0.073 0.239
REM latency, min 104.50 (135.63) 89.50 (61.13) 79.00 (49.00) 131.00 (59.50) 0.034 0.199 0.474
Stage 1 sleep, min 33.75 (23.75) 47.00 (42.25) 33.00 (40.00) 53.00 (57.50) 0.097 0.534 0.678
Stage 2 sleep, min 221.31 ± 13.95 276.38 ± 16.26 222.36 ± 25.37 205.86 ± 14.88 0.004 0.117 0.972
Deep sleep, min 30.50 (15.00) 46.25 (48.63) 33.50 (31.00) 38.00 (41.50) 0.001 0.222 0.882
Stage REM, min 60.25 (20.25) 64.75 (10.25) 34.5 (43.50) 43.50 (43.00) 0.010 0.130 0.053
Sleep efficiency, % 74.40 (16.93) 85.60 (12.23) 84.90 (19.90) 75.00 (22.70) 0.021 0.937 0.495
Sleep maintenance efficiency, % 78.04 ± 4.11 88.30 ± 2.50 88.15 ± 2.45 90.58 ± 2.22 0.056 0.158 0.039

Note: The normally distributed data were expressed as mean ± standard error and the nonnormally distributed data were expressed as median (interquartile range). P1, comparison of various PSG indicators between pre- and post-treatment in the Shumian capsule group; P2, comparison of various PSG indicators between pre- and post-treatment in the placebo group; P3, comparison of various PSG indicators between the Shumian capsule group and the placebo group before treatment.

Abbreviations: PSG, polysomnography; REM, rapid-eye-movement.